144 related articles for article (PubMed ID: 28317148)
21. General aspects and mechanisms of peripheral neuropathy associated with bortezomib in patients with newly diagnosed multiple myeloma.
Broyl A; Jongen JL; Sonneveld P
Semin Hematol; 2012 Jul; 49(3):249-57. PubMed ID: 22726548
[TBL] [Abstract][Full Text] [Related]
22. Subcutaneous versus intravenous bortezomib in two different induction therapies for newly diagnosed multiple myeloma: an interim analysis from the prospective GMMG-MM5 trial.
Merz M; Salwender H; Haenel M; Mai EK; Bertsch U; Kunz C; Hielscher T; Blau IW; Scheid C; Hose D; Seckinger A; Jauch A; Hillengass J; Raab MS; Schurich B; Munder M; Schmidt-Wolf IG; Gerecke C; Lindemann HW; Zeis M; Weisel K; Duerig J; Goldschmidt H
Haematologica; 2015 Jul; 100(7):964-9. PubMed ID: 25840597
[TBL] [Abstract][Full Text] [Related]
23. [Management of proteasome inhibitor-induced peripheral neuropathy].
Takamatsu Y
Nihon Rinsho; 2015 Jan; 73(1):137-41. PubMed ID: 25626319
[TBL] [Abstract][Full Text] [Related]
24. Treatment-related peripheral neuropathy in multiple myeloma: the challenge continues.
Delforge M; Bladé J; Dimopoulos MA; Facon T; Kropff M; Ludwig H; Palumbo A; Van Damme P; San-Miguel JF; Sonneveld P
Lancet Oncol; 2010 Nov; 11(11):1086-95. PubMed ID: 20932799
[TBL] [Abstract][Full Text] [Related]
25. [Incidence and Risk of Peripheral Neuropathy Caused by Intravenous and Subcutaneous Injection of Bortezomib].
Liu ZQ; Xia HL; Li CJ; Xia L
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2019 Oct; 27(5):1654-1663. PubMed ID: 31607328
[TBL] [Abstract][Full Text] [Related]
26. Efficacy and safety of subcutaneous versus intravenous bortezomib in multiple myeloma: a meta-analysis
.
Hu B; Zhou Q; Wu T; Zhuang L; Yi L; Cao J; Yang X; Wang J
Int J Clin Pharmacol Ther; 2017 Apr; 55(4):329-338. PubMed ID: 28079515
[TBL] [Abstract][Full Text] [Related]
27. Role of a pre-existing neuropathy on the course of bortezomib-induced peripheral neurotoxicity.
Lanzani F; Mattavelli L; Frigeni B; Rossini F; Cammarota S; Petrò D; Jann S; Cavaletti G
J Peripher Nerv Syst; 2008 Dec; 13(4):267-74. PubMed ID: 19192066
[TBL] [Abstract][Full Text] [Related]
28. Reversibility of symptomatic peripheral neuropathy with bortezomib in the phase III APEX trial in relapsed multiple myeloma: impact of a dose-modification guideline.
Richardson PG; Sonneveld P; Schuster MW; Stadtmauer EA; Facon T; Harousseau JL; Ben-Yehuda D; Lonial S; Goldschmidt H; Reece D; Bladé J; Boccadoro M; Cavenagh JD; Boral AL; Esseltine DL; Wen PY; Amato AA; Anderson KC; San Miguel J
Br J Haematol; 2009 Mar; 144(6):895-903. PubMed ID: 19170677
[TBL] [Abstract][Full Text] [Related]
29. Treatment of multiple myeloma: thalidomide-, bortezomib-, and lenalidomide-induced peripheral neuropathy.
Koeppen S
Oncol Res Treat; 2014; 37(9):506-13. PubMed ID: 25231692
[TBL] [Abstract][Full Text] [Related]
30. Bortezomib-induced peripheral neurotoxicity in human multiple myeloma-bearing mice.
Meregalli C; Carozzi VA; Sala B; Chiorazzi A; Canta A; Oggioni N; Rodriguez-Menendez V; Ballarini E; Ceresa C; Nicolini G; Crippa L; Orciani M; Cavaletti G; Marmiroli P
J Biol Regul Homeost Agents; 2015; 29(1):115-24. PubMed ID: 25864747
[TBL] [Abstract][Full Text] [Related]
31. Mechanistic Involvement of Inflammation in Bortezomib-induced Peripheral Neuropathy.
Goel L; Gupta P; Pahuja M
Comb Chem High Throughput Screen; 2022; 25(10):1595-1600. PubMed ID: 35611787
[TBL] [Abstract][Full Text] [Related]
32. Genetic determinants of chronic oxaliplatin-induced peripheral neurotoxicity: a genome-wide study replication and meta-analysis.
Terrazzino S; Argyriou AA; Cargnin S; Antonacopoulou AG; Briani C; Bruna J; Velasco R; Alberti P; Campagnolo M; Lonardi S; Cortinovis D; Cazzaniga M; Santos C; Kalofonos HP; Canonico PL; Genazzani AA; Cavaletti G
J Peripher Nerv Syst; 2015 Mar; 20(1):15-23. PubMed ID: 25858589
[TBL] [Abstract][Full Text] [Related]
33. Upregulation of CCL2 via ATF3/c-Jun interaction mediated the Bortezomib-induced peripheral neuropathy.
Liu C; Luan S; OuYang H; Huang Z; Wu S; Ma C; Wei J; Xin W
Brain Behav Immun; 2016 Mar; 53():96-104. PubMed ID: 26554515
[TBL] [Abstract][Full Text] [Related]
34. Neurotoxicity of bortezomib therapy in multiple myeloma: a single-center experience and review of the literature.
Badros A; Goloubeva O; Dalal JS; Can I; Thompson J; Rapoport AP; Heyman M; Akpek G; Fenton RG
Cancer; 2007 Sep; 110(5):1042-9. PubMed ID: 17654660
[TBL] [Abstract][Full Text] [Related]
35. Genetic variation associated with bortezomib-induced peripheral neuropathy.
Favis R; Sun Y; van de Velde H; Broderick E; Levey L; Meyers M; Mulligan G; Harousseau JL; Richardson PG; Ricci DS
Pharmacogenet Genomics; 2011 Mar; 21(3):121-9. PubMed ID: 21228734
[TBL] [Abstract][Full Text] [Related]
36. Bortezomib induced peripheral neuropathy and single nucleotide polymorphisms in PKNOX1.
Zhou X; Han S; Cebulla N; Haertle L; Steinhardt MJ; Schirmer D; Runau E; Flamm L; Terhorst C; Jähnel L; Vogt C; Nerreter S; Teufel E; Stanojkovska E; Mersi J; Munawar U; Schindehütte M; Blum R; Reinhold AK; Scherf-Clavel O; Rittner HL; Pham M; Rasche L; Einsele H; Sommer C; Kortüm KM
Biomark Res; 2023 May; 11(1):52. PubMed ID: 37194045
[TBL] [Abstract][Full Text] [Related]
37. Bortezomib-induced painful neuropathy in rats: a behavioral, neurophysiological and pathological study in rats.
Meregalli C; Canta A; Carozzi VA; Chiorazzi A; Oggioni N; Gilardini A; Ceresa C; Avezza F; Crippa L; Marmiroli P; Cavaletti G
Eur J Pain; 2010 Apr; 14(4):343-50. PubMed ID: 19695912
[TBL] [Abstract][Full Text] [Related]
38. Polymorphisms contribution to the determination of significant risk of specific toxicities in multiple myeloma.
Almási M; Sevcíková S; Sváhová H; Sábláková B; Májková P; Hájek R
Klin Onkol; 2011; 24 Suppl():S39-42. PubMed ID: 21923063
[TBL] [Abstract][Full Text] [Related]
39. Association of an inherited genetic variant with vincristine-related peripheral neuropathy in children with acute lymphoblastic leukemia.
Diouf B; Crews KR; Lew G; Pei D; Cheng C; Bao J; Zheng JJ; Yang W; Fan Y; Wheeler HE; Wing C; Delaney SM; Komatsu M; Paugh SW; McCorkle JR; Lu X; Winick NJ; Carroll WL; Loh ML; Hunger SP; Devidas M; Pui CH; Dolan ME; Relling MV; Evans WE
JAMA; 2015 Feb; 313(8):815-23. PubMed ID: 25710658
[TBL] [Abstract][Full Text] [Related]
40. Bortezomib subcutaneous injection in combination regimens for myeloma or systemic light-chain amyloidosis: a retrospective chart review of response rates and toxicity in newly diagnosed patients.
Shah G; Kaul E; Fallo S; Cossor F; Smith H; Sprague K; Klein A; Miller K; Comenzo R
Clin Ther; 2013 Oct; 35(10):1614-20. PubMed ID: 24075726
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
